- Home
- OKUR vs PEPG Comparison
OKUR vs PEPG Comparison
Compare OKUR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- PEPG
- Stock Information
- Founded
- OKUR 2011
- PEPG 2018
- Country
- OKUR United States
- PEPG United States
- Employees
- OKUR N/A
- PEPG N/A
- Industry
- OKUR
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- PEPG Health Care
- Exchange
- OKUR NYSE
- PEPG Nasdaq
- Market Cap
- OKUR 234.2M
- PEPG 250.3M
- IPO Year
- OKUR N/A
- PEPG 2022
- Fundamental
- Price
- OKUR $15.99
- PEPG $4.32
- Analyst Decision
- OKUR Strong Buy
- PEPG Buy
- Analyst Count
- OKUR 2
- PEPG 3
- Target Price
- OKUR $37.50
- PEPG $14.67
- AVG Volume (30 Days)
- OKUR 58.1K
- PEPG 133.3K
- Earning Date
- OKUR 11-07-2024
- PEPG 11-07-2024
- Dividend Yield
- OKUR N/A
- PEPG N/A
- EPS Growth
- OKUR N/A
- PEPG N/A
- EPS
- OKUR N/A
- PEPG N/A
- Revenue
- OKUR N/A
- PEPG N/A
- Revenue This Year
- OKUR N/A
- PEPG N/A
- Revenue Next Year
- OKUR N/A
- PEPG N/A
- P/E Ratio
- OKUR N/A
- PEPG N/A
- Revenue Growth
- OKUR N/A
- PEPG N/A
- 52 Week Low
- OKUR $9.80
- PEPG $4.00
- 52 Week High
- OKUR $77.60
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- PEPG 23.52
- Support Level
- OKUR N/A
- PEPG $4.00
- Resistance Level
- OKUR N/A
- PEPG $4.77
- Average True Range (ATR)
- OKUR 0.00
- PEPG 0.56
- MACD
- OKUR 0.00
- PEPG -0.05
- Stochastic Oscillator
- OKUR 0.00
- PEPG 9.14
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.